Italy withdraws marketing permission for Celecoxib Maxmind at company's request
Italy's medicines agency AIFA published a notice on 7 November 2026 confirming that the marketing permission for the human medicine Celecoxib Maxmind is being revoked at the request of its holder. The company itself gave up the authorization, so the drug is no longer approved for sale in Italy. The notice carries reference number 26A05793.
This summary was generated by AI; the official source prevails.
What does it mean?
Celecoxib Maxmind is a painkiller and anti-inflammatory medicine. Its maker has asked Italy to cancel its permission to be sold there, so it will no longer be legally sold in Italy under that approval.
Who is affected?
Patients who use Celecoxib Maxmind and pharmacies that stock it in Italy.
What changes?
Before, Celecoxib Maxmind was authorized for sale in Italy; now its authorization is being revoked at the company's request.